Moderna(US:MRNA) Xin Lang Cai Jing·2026-02-13 13:45Core Insights - Moderna (MRNA.US) has several key events to watch in 2026, including financial performance, vaccine approvals, and clinical data releases Financial Performance - The company plans to release its Q4 and full-year 2025 financial report on February 13, 2026 [2] Project Advancements - In the seasonal vaccine sector, the independent flu vaccine mRNA-1010 is expected to receive regulatory approval in multiple regions in 2026 [3] - The RSV vaccine mRESVIA is anticipated to have Phase III clinical trial data available in 2026 [3] Product Development Progress - In oncology, the personalized cancer vaccine mRNA-4157, developed in collaboration with Merck, may announce Phase III clinical trial data in 2026 [4] - The company's independently developed cancer vaccine mRNA-4359 is expected to have potential Phase II clinical data released in 2026 [4] - Ongoing Phase II/III clinical trials for indications such as non-small cell lung cancer will continue [4] Rare Disease Initiatives - The therapy mRNA-3927 for propionic acidemia has achieved target enrollment for its registration study, with data expected in 2026 [5] - The clinical Phase III study for the norovirus vaccine mRNA-1403 will undergo interim analysis in 2026 [5]